Ascendis Pharma AS (BSP:A1SN34) E10: R$0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:A1SN34 Ascendis Pharma AS BSP:A1SN34
56 GF Score
Price R$92.20
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS E10?

Ascendis Pharma AS BSP:A1SN34 56 E10 is R$0.00 as of Mar. 2026. GuruFocus rates BSP:A1SN34 with a GF Score™ of 56/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ascendis Pharma AS's adjusted earnings per share data for the three months ended in Mar. 2026 was R$58.946. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is R$0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-22), Ascendis Pharma AS's current stock price is R$92.20. Ascendis Pharma AS's E10 for the quarter that ended in Mar. 2026 was R$0.00. Ascendis Pharma AS's Shiller PE Ratio of today is .


Ascendis Pharma AS  (BSP:A1SN34) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ascendis Pharma AS E10 Related Terms


Ascendis Pharma AS E10 Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS E10 Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -2.01 -2.86 -2.64

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.79 -2.64 -2.56 -2.64 0.00

BSP:A1SN34 vs JAZZ, BBIO, EXEL: E10 Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Shiller PE Ratio falls into.


BSP:A1SN34
56GF Score
Ascendis Pharma AS BSP:A1SN34
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ascendis Pharma AS's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=58.946/121.6800*121.6800
=58.946

Current CPI (Mar. 2026) = 121.6800.

Ascendis Pharma AS Quarterly Data

per share eps CPI Adj_EPS
201606 -2.039 100.600 -2.466
201609 -2.629 100.200 -3.193
201612 -1.804 100.300 -2.189
201703 -2.609 101.200 -3.137
201706 -3.481 101.200 -4.185
201709 -3.883 101.800 -4.641
201712 -3.587 101.300 -4.309
201803 -4.326 101.700 -5.176
201806 -2.423 102.300 -2.882
201809 -3.883 102.400 -4.614
201812 -3.358 102.100 -4.002
201903 -5.381 102.900 -6.363
201906 -5.446 102.900 -6.440
201909 -2.405 102.900 -2.844
201912 -7.753 102.900 -9.168
202003 -7.127 103.300 -8.395
202006 -11.510 103.200 -13.571
202009 -14.693 103.500 -17.274
202012 -16.523 103.400 -19.444
202103 -7.849 104.300 -9.157
202106 -15.146 105.000 -17.552
202109 -9.130 105.800 -10.500
202112 -11.949 106.600 -13.639
202203 -12.112 109.900 -13.410
202206 -7.790 113.600 -8.344
202209 -15.731 116.400 -16.445
202212 -20.559 115.900 -21.584
202303 -11.042 117.300 -11.454
202306 -11.359 116.400 -11.874
202309 -15.180 117.400 -15.733
202312 -8.229 116.700 -8.580
202403 -12.450 118.400 -12.795
202406 -12.813 118.500 -13.157
202409 -10.572 118.900 -10.819
202412 -4.089 118.900 -4.185
202503 -9.835 120.200 -9.956
202506 -5.245 120.700 -5.288
202509 -6.295 121.600 -6.299
202512 -3.514 121.200 -3.528
202603 58.946 121.680 58.946

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of R$0.00 mean?
Ascendis Pharma AS (BSP:A1SN34) has a E10 of R$0.00 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's E10 too high?
Ascendis Pharma AS's current E10 is R$0.00. Overall, Ascendis Pharma AS has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's E10 compare to JAZZ and BBIO?
Ascendis Pharma AS's E10 of R$0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current E10 is R$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (BSP:A1SN34) has a current E10 of R$0.00. The current E10 is R$0.00. Ascendis Pharma AS's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Ascendis Pharma AS (BSP:A1SN34), the current E10 is R$0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges ASND:USA
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
56GF Score

Get the complete analysis for BSP:A1SN34

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$92.20
Price